MoonLake Immunotherapeutics (NASDAQ:MLTX) price on Friday, May 02, rose 2.12% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $42.32.
A look at the stock’s price movement, the close in the last trading session was $41.44, moving within a range at $39.8574 and $42.88. The beta value (5-Year monthly) was 1.315. Turning to its 52-week performance, $58.26 and $31.42 were the 52-week high and 52-week low respectively. Overall, MLTX moved 11.22% over the past month.
MoonLake Immunotherapeutics’s market cap currently stands at around $2.72 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-25.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MLTX is a 50% Sell. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 5 recommend MLTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MLTX’s current price about 11.30% and 8.66% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 62.68, while 7-day volatility ratio is 5.50% and 7.02% in the 30-day chart. Further, MoonLake Immunotherapeutics (MLTX) has a beta value of 1.31, and an average true range (ATR) of 2.26. Analysts have given the company’s stock an average 52-week price target of $67, forecast between a low of $67 and high of $67. Looking at the price targets, the low is -58.32% off current price level while to achieve the yearly target high, price needs to move -58.32%. Nonetheless, investors will most likely welcome a -58.32% jump to $67 which is the analysts’ median price.
If we refocus on MoonLake Immunotherapeutics (NASDAQ:MLTX), historical trading data shows that trading volumes averaged 0.5 over the past 10 days and 421.65K over the past 3 months. The company’s latest data on shares outstanding shows there are 63.08 million shares.
The 16.60% of MoonLake Immunotherapeutics’s shares are in the hands of company insiders while institutional holders own 100.18% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.63 million on 2025-04-15, giving us a short ratio of 12.63. The data shows that as of 2025-04-15 short interest in MoonLake Immunotherapeutics (MLTX) stood at 2345.0 of shares outstanding, with shares short falling to 7.24 million registered in 2025-03-14. Current price change has pushed the stock -21.85% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MLTX stock continues to rise going into the next quarter.
